Vanguard Global Advisers
ACAD icon

Vanguard Global Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Vanguard Global Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Sell
47,957
-1,776
-4% -$39.1K ﹤0.01% 1621
2026
Q1 		$1.11M Buy
+49,733
New +$1.19M ﹤0.01% 1598

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Global Advisers's ACAD Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Acadia Pharmaceuticals (ACAD) stake by 3.6% in Q2 2026, selling an estimated $39.1K and leaving 47,957 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1621.

Vanguard Global Advisers first reported a position in ACAD in Q1 2026 and has held it in 2 quarters since. 349 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Vanguard Global Advisers held 47,957 shares of Acadia Pharmaceuticals worth $1.21M as of Q2 2026.
  • Vanguard Global Advisers sold 1,776 Acadia Pharmaceuticals shares in Q2 2026, an estimated $39.1K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1621 holding.
  • Vanguard Global Advisers first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 349 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.